ArticleJournal of clinical laboratory analysis2026
Soluble B7-H6 as a Novel Diagnostic Biomarker for Post-Hepatitis B Cirrhosis: A Clinical Value Study.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the diagnostic value of soluble B7-H6 (sB7-H6) as a biomarker for post-hepatitis B cirrhosis (LC) and to compare its performance with conventional non-invasive biomarkers, including FIB-4 and APRI.
methodsA prospective cohort study was conducted with 159 patients diagnosed with HBV-related liver diseases, including 77 with chronic hepatitis B (CHB) and 82 with post-hepatitis B cirrhosis (LC). Serum sB7-H6 levels were quantified using enzyme-linked immunosorbent assay (ELISA). The diagnostic performance of sB7-H6 was evaluated through receiver operating characteristic (ROC) curve analysis. The diagnostic accuracy of sB7-H6, both alone and in combination with FIB-4, was compared to the traditional biomarkers APRI and FIB-4.
resultsSerum sB7-H6 levels increased progressively with disease severity, with the highest levels observed in the LC group. The area under the ROC curve (AUC) for sB7-H6 alone in diagnosing cirrhosis was 0.87, which was superior to both APRI (AUC = 0.75) and FIB-4 (AUC = 0.79). The combined model of sB7-H6 and FIB-4 demonstrated improved diagnostic performance, achieving an AUC of 0.92, with sensitivity of 85.4% and specificity of 88.0%.
conclusionSerum sB7-H6 is a promising, non-invasive biomarker for diagnosing post-hepatitis B cirrhosis, outperforming traditional biomarkers such as FIB-4 and APRI. The combined model of sB7-H6 and FIB-4 provides superior diagnostic accuracy and holds significant potential for clinical use in the early detection and risk stratification of liver cirrhosis in HBV-infected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.